Compare Charles River Laboratories Intl. Inc (CRL) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Western Alliance Bancorporation — how do they compare? Charles River Laboratories Intl. Inc trades at $287.58 (market cap $13.46B), while Western Alliance Bancorporation trades at $82.63 (market cap $8.89B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.06% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | WAL | |
|---|---|---|
Market Cap | $13.46B | $8.89B |
Sector | Health | Financials |
52-Week High | $282.00 | $96.08 |
52-Week Low | $145.57 | $66.70 |
Enterprise Value | $16.30B | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Western Alliance Bancorporation (WAL) trades at $82.18, up 2.11% today, with a neutral technical signal and bullish moving averages. The stock shows solid fundamentals with a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX™ and recognition as Arizona's top bank by Forbes in 2026.
WAL presents a compelling investment case with strong analyst support (79% buy rating) and a consensus price target of $93.86, implying 14% upside. Risks include Q2 2026 EPS miss and negative operating cash flow in 2025, but improving 2026 projections and institutional interest suggest growth potential amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
